SK50497A3 - Use of £r-(z)|-alpha-(methoxyimino)-alpha-(1-azabicyclo £2.2.2| oct-3-yl) acetonitrile and pharmaceutical composition containing same - Google Patents
Use of £r-(z)|-alpha-(methoxyimino)-alpha-(1-azabicyclo £2.2.2| oct-3-yl) acetonitrile and pharmaceutical composition containing same Download PDFInfo
- Publication number
- SK50497A3 SK50497A3 SK504-97A SK50497A SK50497A3 SK 50497 A3 SK50497 A3 SK 50497A3 SK 50497 A SK50497 A SK 50497A SK 50497 A3 SK50497 A3 SK 50497A3
- Authority
- SK
- Slovakia
- Prior art keywords
- disease
- pharmaceutically acceptable
- alzheimer
- acetonitrile
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9421472A GB9421472D0 (en) | 1994-10-25 | 1994-10-25 | Novel methods |
PCT/EP1995/004082 WO1996012486A1 (en) | 1994-10-25 | 1995-10-17 | Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
SK50497A3 true SK50497A3 (en) | 1997-09-10 |
Family
ID=10763350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK504-97A SK50497A3 (en) | 1994-10-25 | 1995-10-17 | Use of £r-(z)|-alpha-(methoxyimino)-alpha-(1-azabicyclo £2.2.2| oct-3-yl) acetonitrile and pharmaceutical composition containing same |
Country Status (22)
Country | Link |
---|---|
US (1) | US5891887A (ko) |
EP (1) | EP0786998B1 (ko) |
JP (1) | JPH10509697A (ko) |
KR (1) | KR100393365B1 (ko) |
CN (1) | CN1085529C (ko) |
AT (1) | ATE214926T1 (ko) |
AU (1) | AU698695B2 (ko) |
BG (1) | BG101500A (ko) |
BR (1) | BR9509433A (ko) |
CZ (1) | CZ287370B6 (ko) |
DE (1) | DE69526102T2 (ko) |
DK (1) | DK0786998T3 (ko) |
ES (1) | ES2173977T3 (ko) |
GB (1) | GB9421472D0 (ko) |
HK (1) | HK1002057A1 (ko) |
HU (1) | HUT77007A (ko) |
NO (1) | NO312055B1 (ko) |
NZ (1) | NZ295155A (ko) |
PT (1) | PT786998E (ko) |
SK (1) | SK50497A3 (ko) |
WO (1) | WO1996012486A1 (ko) |
ZA (1) | ZA958946B (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU751607B2 (en) * | 1995-07-29 | 2002-08-22 | Smithkline Beecham Plc | Method of treatment of dementia |
GB9619074D0 (en) * | 1996-09-12 | 1996-10-23 | Smithkline Beecham Plc | Composition |
DE19641180A1 (de) * | 1996-09-24 | 1998-03-26 | Schering Ag | Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung |
AU748396C (en) * | 1998-03-11 | 2003-01-23 | Smithkline Beecham Corporation | Composition |
GB9815383D0 (en) * | 1998-07-15 | 1998-09-16 | Smithkline Beecham Plc | Novel method of treatment |
US6245884B1 (en) * | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
US7816149B2 (en) * | 2004-03-29 | 2010-10-19 | Applied Photonics Worldwide, Inc. | Nanobioprocessor for protein and cell therapy |
GB0428170D0 (en) * | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Mono and Combination Therapy |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG48315A1 (en) * | 1989-04-13 | 1998-04-17 | Beecham Group Plc | Novel compounds |
US5385915A (en) * | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
US5242932A (en) * | 1991-12-17 | 1993-09-07 | The Rockefeller University | Treatment of amyloidosis associated with alzheimer disease |
JPH0725786A (ja) * | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
MX9300875A (es) * | 1992-02-20 | 1993-08-31 | Smithkline Beecham Plc | Procedimiento para la preparacion de compuestos azabiciclicos. |
WO1994009370A1 (en) * | 1992-10-09 | 1994-04-28 | Massachusetts Institute Of Technology | Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors |
GB9409705D0 (en) * | 1994-05-14 | 1994-07-06 | Smithkline Beecham Plc | Novel compounds |
-
1994
- 1994-10-25 GB GB9421472A patent/GB9421472D0/en active Pending
-
1995
- 1995-10-17 JP JP8513628A patent/JPH10509697A/ja not_active Ceased
- 1995-10-17 WO PCT/EP1995/004082 patent/WO1996012486A1/en active IP Right Grant
- 1995-10-17 PT PT95936515T patent/PT786998E/pt unknown
- 1995-10-17 CZ CZ19971251A patent/CZ287370B6/cs not_active IP Right Cessation
- 1995-10-17 HU HU9701815A patent/HUT77007A/hu unknown
- 1995-10-17 SK SK504-97A patent/SK50497A3/sk unknown
- 1995-10-17 US US08/836,013 patent/US5891887A/en not_active Expired - Fee Related
- 1995-10-17 CN CN95196837A patent/CN1085529C/zh not_active Expired - Fee Related
- 1995-10-17 AT AT95936515T patent/ATE214926T1/de not_active IP Right Cessation
- 1995-10-17 ES ES95936515T patent/ES2173977T3/es not_active Expired - Lifetime
- 1995-10-17 BR BR9509433A patent/BR9509433A/pt not_active Application Discontinuation
- 1995-10-17 DE DE69526102T patent/DE69526102T2/de not_active Expired - Fee Related
- 1995-10-17 AU AU38431/95A patent/AU698695B2/en not_active Ceased
- 1995-10-17 KR KR1019970702700A patent/KR100393365B1/ko not_active IP Right Cessation
- 1995-10-17 EP EP95936515A patent/EP0786998B1/en not_active Expired - Lifetime
- 1995-10-17 NZ NZ295155A patent/NZ295155A/en unknown
- 1995-10-17 DK DK95936515T patent/DK0786998T3/da active
- 1995-10-23 ZA ZA958946A patent/ZA958946B/xx unknown
-
1997
- 1997-04-24 NO NO19971899A patent/NO312055B1/no not_active IP Right Cessation
- 1997-05-20 BG BG101500A patent/BG101500A/xx unknown
-
1998
- 1998-02-05 HK HK98100893A patent/HK1002057A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO971899D0 (no) | 1997-04-24 |
WO1996012486A1 (en) | 1996-05-02 |
GB9421472D0 (en) | 1994-12-07 |
NO971899L (no) | 1997-04-24 |
JPH10509697A (ja) | 1998-09-22 |
AU698695B2 (en) | 1998-11-05 |
DE69526102T2 (de) | 2002-10-31 |
CZ125197A3 (en) | 1997-07-16 |
DE69526102D1 (de) | 2002-05-02 |
HUT77007A (hu) | 1998-03-02 |
EP0786998A1 (en) | 1997-08-06 |
AU3843195A (en) | 1996-05-15 |
CN1170365A (zh) | 1998-01-14 |
ATE214926T1 (de) | 2002-04-15 |
EP0786998B1 (en) | 2002-03-27 |
HK1002057A1 (en) | 1998-07-31 |
CZ287370B6 (en) | 2000-11-15 |
NO312055B1 (no) | 2002-03-11 |
KR100393365B1 (ko) | 2003-12-18 |
KR970706816A (ko) | 1997-12-01 |
BR9509433A (pt) | 1997-09-16 |
ZA958946B (en) | 1996-08-20 |
NZ295155A (en) | 2000-07-28 |
ES2173977T3 (es) | 2002-11-01 |
PT786998E (pt) | 2002-09-30 |
DK0786998T3 (da) | 2002-07-15 |
CN1085529C (zh) | 2002-05-29 |
MX9703077A (es) | 1997-07-31 |
BG101500A (en) | 1998-01-30 |
US5891887A (en) | 1999-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Narita et al. | Interactions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain | |
Solomon et al. | Induction in mice of human light-chain-associated amyloidosis. | |
EP1379269B1 (en) | Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease | |
US20010006972A1 (en) | Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome | |
Nagasawa et al. | . beta.-Substituted cysteines as sequestering agents for ethanol-derived acetaldehyde in vivo | |
Nunzi et al. | Immunopathological studies on alopecia areata | |
Goldstein et al. | Binding interactions of ergot alkaloids with monoaminergic receptors in the brain | |
SK50497A3 (en) | Use of £r-(z)|-alpha-(methoxyimino)-alpha-(1-azabicyclo £2.2.2| oct-3-yl) acetonitrile and pharmaceutical composition containing same | |
EP2535049A1 (en) | Tadalafil for the treatment of dementia | |
EP0873753A1 (en) | Use of NK-1 receptor antagonists for the manufacture of a medicament in the treatment of symptoms of irritable bowel syndrome | |
Syvälahti et al. | Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung | |
EP0557290A1 (en) | Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss | |
KR20230096003A (ko) | 만성 ssri 레지멘 후 실로시빈에 대한 민감도를 증가시키기 위한 벤조디아제핀의 사용 | |
KR20000035446A (ko) | 세포접착분자 발현억제제 | |
Syvälahti et al. | Interaction of psychotropic drugs with brain muscarinic cholinoceptors: similarities of biperiden with pirenzepine in receptor binding properties | |
Rius et al. | Acute ethanol effect on calcium antagonist binding in rat brain | |
US6544565B2 (en) | Use of Valeriana for the treatment of Restless Leg Syndrome and related disorders | |
WO2005013910A2 (en) | Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors | |
Leysen et al. | Opposite regulation of serotonin-S2 and dopamine-D2 receptors in rat brain following chronic receptor blockade | |
Arranz et al. | Characterization of the 5-HT 4 binding site in human brain | |
MXPA97003077A (en) | Use of acetonitrila [r- (z)] - alpha- (metoximino) -alfa- (1-azabiciclo [2.2.2.] oct-3-ilo) to reduce the formation of beta a4 amylide in alzhei's disease | |
Bhattacharya et al. | Clonidine-induced automutilation in mice as a laboratory model for clinical self-injurious behaviour | |
AU758936B2 (en) | Method of treatment | |
Viglione et al. | Lambert–Eaton syndrome: antigen–antibody interaction and calcium current inhibition in chromaffin cells | |
DePetrillo | Effects of chronic alcohol use and age on human lymphocyte protein kinase C activity |